In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: Ibuprofen and ketoprofen

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 7, 2012, Pages 366-377

  Tsume, Yasuhiro ^a   Langguth, Peter ^b   Garcia Arieta, Alfredo ^c   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Division de Farmacologia y Evaluacion Clinica   (Spain)

Author keywords

dissolution media; GastroPlus; ibuprofen; in vitro dissolution; ketoprofen; pH; simulation; weak acid

Indexed keywords

BUFFER; IBUPROFEN; KETOPROFEN; PHOSPHATE BUFFERED SALINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPUTER MODEL; CONCENTRATION (PARAMETERS); DRUG ABSORPTION; DRUG RELEASE; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; MAXIMUM PLASMA CONCENTRATION; PKA; SIMULATION; STOMACH PH; TABLET;

ABSORPTION; BIOPHARMACEUTICS; COMPUTER SIMULATION; HUMANS; HYDROGEN-ION CONCENTRATION; IBUPROFEN; INTESTINES; KETOPROFEN; MODELS, BIOLOGICAL; MOUTH MUCOSA; PREDICTIVE VALUE OF TESTS; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 84867101149     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1800     Document Type: Article

References (50)

1. U.S. FDA Department of Health and Human Services Food and Drug Administration Center for Evaluation and Research. Guidances for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.
2. EMA Guideline on the Investigation of Bioequivalence, 2010.
3. Amidon GL, Lennernas H, Shah VP, et al,. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
4. Yazdanian M, Briggs K, Jankovsky C, et al,. The 'high solubility' definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 2004; 21: 293-299.
5. Gupta E, Barends DM, Yamashita E, et al,. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci 2006; 29: 315-324.
6. Polli JE, Abrahamsson BS, Yu LX, et al,. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J 2008; 10: 373-379.
7. Agrawal S, Panchagnula R,. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos 2005; 26: 321-334.
8. Davies NM,. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28: 100-114.
9. Faassen F, Vromans H,. Biowaivers for oral immediate-release products: implications of linear pharmacokinetics. Clin Pharmacokinet 2004; 43: 1117-1126.
10. Kovacevic I, Parojcic J, Homsek I, et al,. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 2008; 6: 40-47.
11. Tubic-Grozdanis M, Bolger MB, Langguth P,. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J 2008; 10: 213-226.
12. Potthast H, Dressman JB, Junginger HE, et al,. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci 2005; 94: 2121-2131.
13. Alvarez C, Nunez I, Torrado JJ, et al,. Investigation on the possibility of biowaivers for ibuprofen. J Pharm Sci 2011; 100: 2343-2349.
14. Mooney KG, Mintun MA, Himmelstein KJ, et al,. Dissolution kinetics of carboxylic acids II: effect of buffers. J Pharm Sci 1981; 70: 22-32.
15. Fallingborg J,. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999; 46: 183-196.
16. Vertzoni M, Fotaki N, Kostewicz E, et al,. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J Pharm Pharmacol 2004; 56: 453-462.
17. The United States Pharmacopeia. USP 24 The National Formulary NF19, 2000.
18. Sheng JJ, McNamara DP, Amidon GL,. Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm 2009; 6: 29-39.
19. Abernethy DR, Greenblatt DJ,. Ibuprofen disposition in obese individuals. Arthritis Rheum 1985; 28: 1117-1121.
20. Avdeef A, Box KJ, Comer JE, et al,. pH-metric log P 11. pKa determination of water-insoluble drugs in organic solvent-water mixtures. J Pharm Biomed Anal 1999; 20: 631-641.
21. Avdeef A, Box KJ, Comer JE, et al,. pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm Res 1998; 15: 209-215.
22. Geisslinger G, Menzel S, Wissel K, et al,. Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate. Br J Clin Pharmacol 1995; 40: 73-75.
23. Herzfeldt CD, Kummel R,. Dissociation constants, solubilities and dissolution rates of some selected nonsteroidal antiinflammatories. Drug Dev Ind Pharm 1983; 9: 767-793.
24. Kasim NA, Whitehouse M, Ramachandran C, et al,. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
25. Sangster J,. Octanol-water partition coefficients, 1993.
26. Lu AT, Frisella ME, Johnson KC,. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res 1993; 10: 1308-1314.
27. Mutalik S, Anju P, Manoj K, et al,. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach. Int J Pharm 2008; 350: 279-290.
28. US FDA Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. FDA Guidance for Industry, 2002.
29. EMA Concept Paper on BCS- Based Biowaiver, 2007.
30. Yu LX, Amidon GL, Polli JE, et al,. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19: 921-925.
31. Davies NM,. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34: 101-154.
32. Dressman JB, Hempenstall J, Reppas C,. The BCS: Where do we go from here? Pharm Technol 2001; 25: 68-76.
33. Aburub A, Risley DS, Mishra D,. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int J Pharm 2008; 347: 16-22.
34. Ghosh LK, Ghosh NC, Chatterjee M, et al,. Product development studies on the tablet formulation of ibuprofen to improve bioavailability. Drug Dev Ind Pharm 1998; 24: 473-477.
35. Kaus LC, Fell JT,. Effect of stress on the gastric emptying of capsules. J Clin Hosp Pharm 1984; 9: 249-251.
36. Kortejarvi H, Shawahna R, Koski A, et al,. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs. J Pharm Sci 2010; 99: 621-625.
37. Oberle RL, Chen TS, Lloyd C, et al,. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 1990; 99: 1275-1282.
38. Ibekwe VC, Fadda HM, McConnell EL, et al,. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res 2008; 25: 1828-1835.
39. Madsen JL, Krogsgaard OW,. Gastrointestinal scintiscanning: dosimetry. Eur J Nucl Med 1989; 15: 260-261.
40. Lee KJ, Vos R, Janssens J, et al,. Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol 2004; 286: G278-G284.
41. Perez de la Cruz Moreno M, Oth M, Deferme S, et al,. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58: 1079-1089.
42. Kalantzi L, Goumas K, Kalioras V, et al,. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/ bioequivalence studies. Pharm Res 2006; 23: 165-176.
43. Persson EM, Gustafsson AS, Carlsson AS, et al,. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 2005; 22: 2141-2151.
44. Corrigan OI, Devlin Y, Butler J,. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Int J Pharm 2003; 254: 147-154.
45. Levis KA, Lane ME, Corrigan OI,. Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. Int J Pharm 2003; 253: 49-59.
46. Galia E, Nicolaides E, Horter D, et al,. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705.
47. Jantratid E, Janssen N, Reppas C, et al,. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 2008; 25: 1663-1676.
48. Karr WG, Abbott WO, Sample AB,. Intubation studies of the human small intestine. IV. Chemical characteristics of the intestinal contents in the fasting state and as influenced by the administration of acids, of alkalies and of water. J Clin Invest 1935; 14: 893-900.
49. Anand O, Yu LX, Conner DP, et al,. Dissolution testing for generic drugs: an FDA perspective. AAPS J 2011; 13: 328-335.
50. Siewert M, Dressman J, Brown CK, et al,. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 2003; 4: E7.